Phase 1 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- (Part 1A only) People with advanced or metastatic breast cancer or other solid tumours whose cancer has spread, and who have already tried all available standard treatments, cannot tolerate them, or have no standard treatments left.
- (Parts 1B and 2A only) People with advanced breast cancer who have received between 1 and 3 prior rounds of systemic (whole-body) treatment for their metastatic disease, with no more than 2 of those rounds being chemotherapy (including certain antibody-based drug treatments).
- (Parts 2B and 2C only) People with advanced breast cancer who are in a region where a specific class of drugs called CDK4/6 inhibitors are not approved or available as a first treatment, and who have never received CDK4/6 inhibitors or any prior systemic treatment for their advanced disease.
- People with breast cancer whose diagnosis has been confirmed through laboratory testing of tissue or cell samples, following recognised medical guidelines.
- Women with metastatic breast cancer who have been through menopause, or who are receiving treatment to suppress ovarian function.
- People whose cancer can be measured on scans using a standard set of assessment criteria.
- People who are in good general health, able to carry out everyday activities with little or no restriction (confirmed with trial site).
- People whose liver, kidneys, and other organs are functioning adequately (confirm with trial site).
Who may not be able to join:
- People who have previously been treated with a specific class of experimental drugs known as KAT6A/B or KAT7 inhibitors or degraders.
- People who have active cancer spread to the membranes surrounding the brain or spinal cord, or who have brain metastases that are not being treated or are not stable.
- People who have had a different cancer diagnosis within the past 3 years, with exceptions for the cancer being studied in this trial and for any localised cancer that has been successfully treated and is unlikely to need further treatment during the study period (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Director, BeOne Medicines
Phone: 877-828-5568
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Part 1: Number of Participants with Adverse Events (AEs); Part 1: Recommended Dose for Expansion (RDFE); Part 2: Overall Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.